May cause bone fracture risk and decreased bone mineral density
Canagliflozin belongs to a class of drugs called sodium-glucose cotransporter-2 (SGLT2) inhibitors. It is used with diet and exercise to lower blood sugar in adults with type 2 diabetes.
Alert: The USFDA warns that this class of drugs may cause increased risk of bone fractures and decreases bone mineral density at the hip and lower spine. The USFDA is continuing to evaluate the risk of bone fractures with other drugs in the SGLT2 inhibitor class, including dapagliflozin and empaglifozin.
Hence, KSPC-DIRC alerts the healthcare professionals to be cautious while prescribing Canagliflozin